Research programme: hearing disorder therapies - AudioCure PharmaAlternative Names: AC-002; AC-102; AC-103; AC-104
Latest Information Update: 17 Jan 2014
At a glance
- Originator AudioCure Pharma
- Class Small molecules
- Mechanism of Action Adenosine triphosphatase stimulants; Antioxidants; Apoptosis inhibitors; Brain-derived neurotrophic factor expression stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hearing disorders
Most Recent Events
- 17 Jan 2014 Preclinical trials in Hearing disorders in Germany (Intratympanic)